Patents by Inventor Guy Krippner

Guy Krippner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Milrinone controlled-release formulation
    Patent number: 11331274
    Abstract: The present invention relates to oral controlled-release formulations of 5-(pyridinyl)-2(1H)-pyridinone compounds and their use in the treatment of a subject with heart failure, a stage, class or manifestation of heart failure, or at risk of developing or exhibiting symptoms of heart failure. The formulations of the invention release the compounds in the range of between 0.1 ?g/kg body weight/minute and 20 ?g/kg body weight/minute.
    Type: Grant
    Filed: January 17, 2020
    Date of Patent: May 17, 2022
    Assignee: Baker Heart and Diabetes Institute
    Inventors: David Martin Kaye, Guy Krippner, Geetha Thanga Mariappan
  • Milrinone controlled-release formulation
    Patent number: 10736853
    Abstract: The present invention relates to oral controlled-release formulations of 5-(pyridinyl)-2(1H)-pyridinone compounds and their use in the treatment of a subject with heart failure, a stage, class or manifestation of heart failure, or at risk of developing or exhibiting symptoms of heart failure. The formulations of the invention release the compounds in the range of between 0.1 ?g/kg body weight/minute and 20 ?g/kg body weight/minute.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: August 11, 2020
    Assignee: Cardiora Pty Ltd.
    Inventors: David Martin Kaye, Guy Krippner, Geetha Thanga Mariappan
  • MILRINONE CONTROLLED-RELEASE FORMULATION
    Publication number: 20200146992
    Abstract: The present invention relates to oral controlled-release formulations of 5-(pyridinyl)-2(1H)-pyridinone compounds and their use in the treatment of a subject with heart failure, a stage, class or manifestation of heart failure, or at risk of developing or exhibiting symptoms of heart failure. The formulations of the invention release the compounds in the range of between 0.1 ?g/kg body weight/minute and 20 ?g/kg body weight/minute.
    Type: Application
    Filed: January 17, 2020
    Publication date: May 14, 2020
    Inventors: David Martin Kaye, Guy Krippner, Geetha Thanga Mariappan
  • Milrinone controlled-release formulation
    Patent number: 10537527
    Abstract: The present invention relates to oral controlled-release formulations of 5-(pyridinyl)-2(1H)-pyridinone compounds and their use in the treatment of a subject with heart failure, a stage, class or manifestation of heart failure, or at risk of developing or exhibiting symptoms of heart failure. The formulations of the invention release the compounds in the range of between 0.1 ?g/kg body weight/minute and 20 ?g/kg body weight/minute.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: January 21, 2020
    Assignee: Cardiora Pty Ltd.
    Inventors: David Martin Kaye, Guy Krippner, Geetha Thanga Mariappan
  • Uses of milrinone controlled-release formulation
    Patent number: 10517833
    Abstract: The present invention relates to oral controlled-release formulations of 5-(pyridinyl)-2(1H)-pyridinone compounds and their use in the treatment of a subject with heart failure, a stage, class or manifestation of heart failure, or at risk of developing or exhibiting symptoms of heart failure. The formulations of the invention release the compounds in the range of between 0.1 ?g/kg body weight/minute and 20 ?g/kg body weight/minute.
    Type: Grant
    Filed: July 6, 2018
    Date of Patent: December 31, 2019
    Assignee: Cardiora Pty Ltd.
    Inventors: David Martin Kaye, Guy Krippner, Geetha Thanga Mariappan
  • MILRINONE CONTROLLED-RELEASE FORMULATION
    Publication number: 20190091156
    Abstract: The present invention relates to oral controlled-release formulations of 5-(pyridinyl)-2(1H)-pyridinone compounds and their use in the treatment of a subject with heart failure, a stage, class or manifestation of heart failure, or at risk of developing or exhibiting symptoms of heart failure. The formulations of the invention release the compounds in the range of between 0.1 ?g/kg body weight/minute and 20 ?g/kg body weight/minute.
    Type: Application
    Filed: November 20, 2018
    Publication date: March 28, 2019
    Inventors: David Martin Kaye, Guy Krippner, Geetha Thanga Mariappan
  • Milrinone controlled-release formulation
    Patent number: 10137093
    Abstract: The present invention relates to oral controlled-release formulations of 5-(pyridinyl)-2(1H)-pyridinone compounds and their use in the treatment of a subject with heart failure, a stage, class or manifestation of heart failure, or at risk of developing or exhibiting symptoms of heart failure. The formulations of the invention release the compounds in the range of between 0.1 ?g/kg body weight/minute and 20 ?g/kg body weight/minute.
    Type: Grant
    Filed: August 16, 2012
    Date of Patent: November 27, 2018
    Assignee: Cardiora Pty Ltd.
    Inventors: David Martin Kaye, Guy Krippner, Geetha Thanga Mariappan
  • METHOD OF WEIGHT REDUCTION
    Publication number: 20180333398
    Abstract: The present disclosure relates generally to the use of methazolamide in therapy. The disclosure particularly relates to regulation of glucose homeostasis and reduction of body mass in patients suffering from or susceptible to diseases and associated conditions, in which undesirably high blood glucose levels are involved or implicated, such as diabetes, syndrome X, hyperglycaemia, vascular disease and kidney disease. The present disclosure further relates to compounds and agents and compositions thereof for use in the treatment methods.
    Type: Application
    Filed: February 9, 2018
    Publication date: November 22, 2018
    Inventors: Ken Walder, Guy Krippner, Geoff Nicholson
  • METHOD OF IMPROVING LIVER FUNCTION
    Publication number: 20180333399
    Abstract: The present disclosure relates generally to the use of methazolamide in therapy. The disclosure further relates to treating liver dysfunction, or improving liver function, in a patient.
    Type: Application
    Filed: April 12, 2018
    Publication date: November 22, 2018
    Inventors: Ken Walder, Guy Krippner, Geoff Nicholson
  • CONTROLLED-RELEASE FORMULATION
    Publication number: 20180325826
    Abstract: The present invention relates to oral controlled-release formulations of 5-(pyridinyl)-2(1H)-pyridinone compounds and their use in the treatment of a subject with heart failure, a stage, class or manifestation of heart failure, or at risk of developing or exhibiting symptoms of heart failure. The formulations of the invention release the compounds in the range of between 0.1 ?g/kg body weight/minute and 20 ?g/kg body weight/minute.
    Type: Application
    Filed: July 6, 2018
    Publication date: November 15, 2018
    Inventors: David Martin Kaye, Guy Krippner, Geetha Thanga Mariappan
  • 8-hydroxy quinoline derivatives
    Patent number: 9302993
    Abstract: The present invention describes a method for the treatment of a neurological condition in a subject which comprises administering to a subject in need thereof a therapeutically effect amount of a compound of the formula or pharmaceutically acceptable salts, hydrates, or solvates thereof.
    Type: Grant
    Filed: October 9, 2014
    Date of Patent: April 5, 2016
    Assignee: PRANA BIOTECHNOLOGY LIMITED
    Inventors: Kevin Jeffrey Barnham, Elisabeth Colette Louise Gautier, Gaik Beng Kok, Guy Krippner
  • Antiviral agents
    Patent number: 9303026
    Abstract: This invention relates to compounds of formula I their salts, and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions comprising these compounds and their use in the treatment of picornavirus infections in mammals, as well as novel intermediates useful in the preparation of the compounds of formula I.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: April 5, 2016
    Assignee: BIOTA SCIENTIFIC MANAGEMENT PTY. LTD.
    Inventors: Keith Watson, Guy Krippner, Pauline Stanislawski, Darryl McConnell
  • 8-HYDROXY QUINOLINE DERIVATIVES
    Publication number: 20150335635
    Abstract: The present invention describes a method for the treatment of a neurological condition in a subject which comprises administering to a subject in need thereof a therapeutically effect amount of a compound of the formula or pharmaceutically acceptable salts, hydrates, or solvates thereof.
    Type: Application
    Filed: August 5, 2015
    Publication date: November 26, 2015
    Applicant: PRANA BIOTECHNOLOGY LIMITED
    Inventors: Kevin Jeffrey BARNHAM, Elisabeth Colette Louise GAUTIER, Gaik Beng KOK, Guy KRIPPNER
  • 8-hydroxy quinoline derivatives
    Patent number: 9169211
    Abstract: The present invention describes a method for the treatment of a neurological condition in a subject which comprises administering to a subject in need thereof a therapeutically effect amount of a compound of the formula or pharmaceutically acceptable salts, hydrates, or solvates thereof.
    Type: Grant
    Filed: October 9, 2014
    Date of Patent: October 27, 2015
    Assignee: PRANA BIOTECHNOLOGY LIMITED
    Inventors: Kevin Jeffrey Barnham, Elisabeth Colette Louise Gautier, Gaik Beng Kok, Guy Krippner
  • METHOD OF WEIGHT REDUCTION
    Publication number: 20150174108
    Abstract: The present disclosure relates generally to the use of methazolamide in therapy. The disclosure particularly relates to regulation of glucose homeostasis and reduction of body mass in patients suffering from or susceptible to diseases and associated conditions, in which undesirably high blood glucose levels are involved or implicated, such as diabetes, syndrome X, hyper-glycaemia, vascular disease and kidney disease. The present disclosure further relates to compounds and agents and compositions thereof for use in the treatment methods.
    Type: Application
    Filed: March 15, 2013
    Publication date: June 25, 2015
    Inventors: Ken Walder, Guy Krippner, Geoff Nicholson
  • METHOD OF IMPROVING LIVER FUNCTION
    Publication number: 20150150855
    Abstract: The present disclosure relates generally to the use of methazolamide in therapy. The disclosure further relates to treating liver dysfunction, or improving liver function, in a patient.
    Type: Application
    Filed: March 15, 2013
    Publication date: June 4, 2015
    Inventors: Ken Walder, Guy Krippner, Geoff Nicholson
  • 8-HYDROXY QUINOLINE DERIVATIVES
    Publication number: 20150094334
    Abstract: The present invention describes a method for the treatment of a neurological condition in a subject which comprises administering to a subject in need thereof a therapeutically effect amount of a compound of the formula or pharmaceutically acceptable salts, hydrates, or solvates thereof.
    Type: Application
    Filed: October 9, 2014
    Publication date: April 2, 2015
    Applicant: PRANA BIOTECHNOLOGY LIMITED
    Inventors: Kevin Jeffrey BARNHAM, Elisabeth Colette Louise GAUTIER, Gaik Beng KOK, Guy KRIPPNER
  • 8-hydroxy quinoline derivatives
    Patent number: 8975278
    Abstract: The present invention describes a method for the treatment of a neurological condition in a subject which comprises administering to a subject in need thereof a therapeutically effect amount of a compound of the formula or pharmaceutically acceptable salts, hydrates, or solvates thereof.
    Type: Grant
    Filed: September 19, 2007
    Date of Patent: March 10, 2015
    Assignee: Prana Biotechnology Limited
    Inventors: Kevin Jeffrey Barnham, Elisabeth Colette Louise Gautier, Gaik Beng Kok, Guy Krippner
  • 8-HYDROXY QUINOLINE DERIVATIVES
    Publication number: 20150025108
    Abstract: The present invention describes a method for the treatment of a neurological condition in a subject which comprises administering to a subject in need thereof a therapeutically effect amount of a compound of the formula or pharmaceutically acceptable salts, hydrates, or solvates thereof.
    Type: Application
    Filed: October 9, 2014
    Publication date: January 22, 2015
    Applicant: PRANA BIOTECHNOLOGY LIMITED
    Inventors: Kevin Jeffrey BARNHAM, Elisabeth Colette Louise GAUTIER, Gaik Beng KOK, Guy KRIPPNER
  • CONTROLLED-RELEASE FORMULATION
    Publication number: 20140328908
    Abstract: The present invention relates to oral controlled-release formulations of 5-(pyridinyl)-2(1H)-pyridinone compounds and their use in the treatment of a subject with heart failure, a stage, class or manifestation of heart failure, or at risk of developing or exhibiting symptoms of heart failure. The formulations of the invention release the compounds in the range of between 0.1 ?g/kg body weight/minute and 20 ?g/kg body weight/minute.
    Type: Application
    Filed: August 16, 2012
    Publication date: November 6, 2014
    Applicant: Baker IDI Heart & Diabetes Institute Holdings Limited
    Inventors: David Martin Kaye, Guy Krippner, Geetha Thanga Mariappan